October 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountscholar.google.com.pr
Global Rank
- -
Country Rank
- -
Category Rank
- -
Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
75.55%
Pages per Visit
1.89
Avg Visit Duration
00:00:36
- Company
- - -
- Industry
- - -
Top 10 scholar.google.com.pr Competitors
The Top 10 Sites Like scholar.google.com.pr in October 2026 are ranked by their affinity to scholar.google.com.pr in terms of keyword traffic, audience targeting, and market overlap
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
Global Rank
#369
10Bounce Rate
31.28%
Pages per Visit
6.01
Avg Visit Duration
00:07:55
Similarity Score
100%Explore options for your family: the YouTube Kids app or a parent supervised account for older kids & teens on YouTube, all with built-in protections.
- Company
- YouTube
Bounce Rate
23.61%
Pages per Visit
11.07
Avg Visit Duration
00:18:45
Similarity Score
86%academia.edu is a place to share and follow research.
- Company
- Academia
Bounce Rate
61.51%
Pages per Visit
2.35
Avg Visit Duration
00:01:41
Similarity Score
80%Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
Global Rank
#407
7Bounce Rate
46.91%
Pages per Visit
3.59
Avg Visit Duration
00:03:06
Similarity Score
76%We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying individual urgency to acquire resources. Treatments varied in the urgency process (frequent moderate versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Benchmarked against random allocation, karma achieves an (almost) Pareto improvement, despite subjects deviating from the theoretically optimal Nash bidding policy: maximum improvement is attained by subjects deviating by up to one karma bid unit on average, and positive improvement with deviations of up to 3-4 units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding being (weakly) favorable. They offer behaviorally robust lower bounds for karma's expected performance in human populations and guide its future implementation.
- Company
- - -
- Industry
- - -
Global Rank
#1,994
145Bounce Rate
39.23%
Pages per Visit
3.17
Avg Visit Duration
00:04:08
Similarity Score
73%indexingmethod_automated - Search Results - PubMed
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
71%the world’s largest collection of open access research papers
- Company
- - -
- Industry
- - -
Global Rank
#36,852
20,099Bounce Rate
26.98%
Pages per Visit
5.13
Avg Visit Duration
00:04:27
Similarity Score
65%Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- Company
- - -
- Industry
- - -
Global Rank
#74,009
9,111Bounce Rate
24.78%
Pages per Visit
3.71
Avg Visit Duration
00:01:07
Similarity Score
62%Learn more about our institutional models for librarians and the benefits for researchers.
- Company
- PLOS
Global Rank
#17,323
1,917Bounce Rate
61.54%
Pages per Visit
1.75
Avg Visit Duration
00:01:42
Similarity Score
61%DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
- Company
- - -
- Industry
- - -
Global Rank
#26,873
5,777Bounce Rate
19.35%
Pages per Visit
4.43
Avg Visit Duration
00:01:51
Similarity Score
59%scholar.google.com.pr's top 5 competitors in October 2026 are: sciencedirect.com, youtube.com, academia.edu, researchgate.net, and more.
According to Similarweb data of monthly visits, scholar.google.com.pr’s top competitor in October 2026 is sciencedirect.com. scholar.google.com.pr 2nd most similar site is youtube.com, and closing off the top 3 is academia.edu.
researchgate.net ranks as the 4th most similar website to scholar.google.com.pr and arxiv.org ranks fifth in October 2026.
The other five competitors in the top 10 list are pubmed.ncbi.nlm.nih.gov, core.ac.uk, scienceopen.com, plos.org, and doaj.org.